Analytical Data
-
Gene name
C9orf30
- Application
-
Alternative Names
C9orf2; C9orf3 TMEFF1; C9orf30 TMEFF1; C9orf30 TMEFF1 fusion Protein; Cancer/testis antigen family 120 member 1; CT120.1; H 7365; H7365; MSANTD3-TMEFF1 readthrough; TEFF 1; TEFF1
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8IYR6
-
Expression Region
1-275aa
-
AA Sequence
MQNNEIIKPAKYFSELEKSILLALVEKYKYVLECKKSDARTIALKQRTWQALAHEYNSQPSVSLRDFKQLKKCWENIKARTKKIMAHERREKVKRSVSPLLSTHVLGKEKIASMLPEQLYFLQSPPEEEPEYHPDASAQESFAVSNRELCDDEKEFIHFPVCEGTSQPEPSCSAVRITANKNYRSKTSQEGALKKMHEEEHHQQMSILQLQLIQMNEVHVAKIQQIERECEMAEEEHRIKMEVLNKKKMYWERKLQTFTKEWPVSSFNRPFPNSP
-
Molecular Weight
58.8 KDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
C9orf30, also known as Chromosome 9 Open Reading Frame 30, has emerged as a protein of interest in various research domains, particularly in neurobiology and cancer studies. Initial discoveries suggested that C9orf30 might play a role in cellular processes such as apoptosis, cell proliferation, and immune responses. Recent studies have implicated C9orf30 in neurodegenerative diseases, notably Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), where mutations in the gene are associated with disease pathology. The protein's function and interactions at the molecular level remain largely unexplored, highlighting a critical gap in our understanding of its biological significance. Researchers are now focusing on producing recombinant C9orf30 protein to facilitate detailed studies into its structural characteristics, functional roles, and potential therapeutic implications. By employing techniques such as recombinant DNA technology, scientists aim to generate a stable and functional version of C9orf30, which can be used in biochemical assays and functional studies. This research not only aids in deciphering the protein’s specific biological functions but also enhances our understanding of its contribution to disease mechanisms, potentially offering avenues for novel therapeutic strategies to combat conditions linked to C9orf30. Overall, the investigation of C9orf30 recombinant proteins stands as a pivotal step towards unraveling the complexity of its role in health and disease.
